A Phase 3 interventional study of Benralizumab and Benralizumab Placebo in Asthma, sponsored by AstraZeneca. Completed at 24 sites in United States. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2018-10-24.
Sponsored by AstraZeneca · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 25th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 15th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 151st largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2016, is one of 121 in phase 3, and was the 210th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination
This study is designed to investigate the potential effect of benralizumab on the antibody response to the seasonal influenza virus vaccine in patients 12-21 years of age with asthma. Benralizumab will be given subcutaneously (SC) at Weeks 0, 4, and 8 weeks, at which time benralizumab levels will reach steady state. Patients will then receive 1 dose of intramuscular (IM) seasonal influenza virus vaccine at Week 8 and samples drawn at Week 8 and Week 12 to measure the antibody response to the influenza virus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
Drug: Benralizumab · Drug: Seasonal influenza virus vaccine
1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
Drug: Benralizumab Placebo · Drug: Seasonal influenza virus vaccine
Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12
To compare the geometric mean fold rises in influenza strain-specific hemagglutination-inhibition responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \[log(z) x\]), where "x" is the postdose HAI antibody titer fold rise from Week 8 and "z" is the natural logarithm.
Time frame: 4 weeks
Postdose Strain-specific Hemagglutination-inhibition Antibody Geometric Mean Titers Obtained at Week 12
To compare the geometric mean titers of hemagglutination-inhibition antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
Time frame: 12 weeks
Proportion of Patients Who Experienced a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Hemagglutination-inhibition Antibody Titer From Week 8 to Week 12
To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in hemagglutination-inhibition antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
Time frame: 4 weeks
Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination-inhibition Antibody Titer ≥40 at Week 12
To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥40-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
Time frame: 12 weeks
Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination Inhibition Antibody Titre ≥320 at Week 12
To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥320-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
Time frame: 12 weeks
Postdose Strain-specific Microneutralization Antibody Geometric Mean Fold Rise From Week 8 to Week 12
To compare the geometric mean fold rises in influenza strain-specific microneutralization antibody responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \[log(z) x\]), where "x" is the postdose microneutralization antibody titer fold rise from Week 8 and "z" is the natural logarithm.
Time frame: 4 weeks
Postdose Strain-specific Serum Microneutralization Antibody Geometric Mean Titers Obtained at Week 12
To compare the geometric mean titers of microneutralization antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
Time frame: 12 weeks
Proportion of Patients Who Experience a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Microneutralization Antibody Titer From Week 8 to Week 12
To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in microneutralization antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
Time frame: 4 weeks
Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12
To compare the change from baseline at Week 12 in mean ACQ-6 score between patients receiving benralizumab 30mg and patients receiving placebo. The ACQ-6 assesses asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short-acting β2 agonist use). Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score is the mean of the responses to each question. Mean scores of ≤0.75 indicate well-controlled asthma, scores between 0.75 and ≤1.5 indicate partly controlled asthma, and a score \>1.5 indicates not well controlled asthma
Time frame: 12 weeks
This study was conducted at 30 study centers in the United States between 01 July 2016 and 24 January 2017
| Milestone | Benralizumab 30mg | Placebo |
|---|---|---|
| Started | 51 | 52 |
| Completed | 50 | 49 |
| Not completed | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
To compare the geometric mean fold rises in influenza strain-specific hemagglutination-inhibition responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \[log(z) x\]), where "x" is the postdose HAI antibody titer fold rise from Week 8 and "z" is the natural logarithm.
| Fold change | Benralizumab 30mg | Placebo |
|---|---|---|
| Influenza A H1N1 | 3.60 ± 1.22 | 3.13 ± 1.22 |
| Influenza A H3N2 | 3.25 ± 1.18 | 3.85 ± 1.18 |
| Influenza B Yamagata lineage | 3.42 ± 1.16 | 3.17 ± 1.16 |
| Influenza B Victoria lineage | 4.08 ± 1.19 | 3.27 ± 1.19 |
To compare the geometric mean titers of hemagglutination-inhibition antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
| Antibody titer | Benralizumab 30mg | Placebo |
|---|---|---|
| Influenza A H1N1 | 521.06 ± 1.13 | 518.60 ± 1.13 |
| Influenza A H3N2 | 170.73 ± 1.15 | 219.35 ± 1.15 |
| Influenza B Yamagata lineage | 61.47 ± 1.13 | 63.15 ± 1.13 |
| Influenza B Victoria lineage | 53.10 ± 1.14 | 66.85 ± 1.14 |
To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in hemagglutination-inhibition antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
| Proportion of Participants | Benralizumab 30mg | Placebo |
|---|---|---|
| Influenza A H1N1 | 0.440 (0.32 to 0.57) | 0.306 (0.20 to 0.43) |
| Influenza A H3N2 | 0.500 (0.38 to 0.62) | 0.490 (0.37 to 0.62) |
| Influenza B Yamagata lineage | 0.480 (0.36 to 0.60) | 0.490 (0.37 to 0.62) |
| Influenza B Victoria lineage | 0.560 (0.43 to 0.68) | 0.408 (0.29 to 0.54) |
To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥40-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
| Proportion of Participants | Benralizumab 30mg | Placebo |
|---|---|---|
| Influenza A H1N1 | 1.00 ± 251.9 | 1.00 ± 191.3 |
| Influenza A H3N2 | 0.980 ± 136.2 | 0.980 ± 168.6 |
| Influenza B Yamagata lineage | 0.860 ± 144.9 | 0.796 ± 115.0 |
| Influenza B Victoria lineage | 0.780 ± 178.7 | 0.878 ± 162.2 |
To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥320-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
| Proportion of Participants | Benralizumab 30mg | Placebo |
|---|---|---|
| Influenza A H1N1 | 0.840 (0.73 to 0.92) | 0.857 (0.75 to 0.93) |
| Influenza A H3N2 | 0.500 (0.38 to 0.62) | 0.612 (0.48 to 0.73) |
| Influenza B Yamagata lineage | 0.020 (0.00 to 0.09) | 0.020 (0.00 to 0.09) |
| Influenza B Victoria lineage | 0.080 (0.03 to 0.17) | 0.041 (0.01 to 0.12) |
To compare the geometric mean fold rises in influenza strain-specific microneutralization antibody responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \[log(z) x\]), where "x" is the postdose microneutralization antibody titer fold rise from Week 8 and "z" is the natural logarithm.
| Fold change | Benralizumab 30mg | Placebo |
|---|---|---|
| Influenza A H1N1 | 5.1 ± 521.4 | 4.4 ± 329.4 |
| Influenza A H3N2 | 3.2 ± 149.8 | 3.6 ± 210.0 |
| Influenza B Yamagata lineage | 2.8 ± 148.9 | 3.2 ± 141.3 |
| Influenza B Victoria lineage | 3.8 ± 224.1 | 3.5 ± 195.3 |
To compare the geometric mean titers of microneutralization antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
| Antibody titer | Benralizumab 30mg | Placebo |
|---|---|---|
| Influenza A H1N1 | 3774.1 ± 181.7 | 3969.1 ± 154.0 |
| Influenza A H3N2 | 4307.5 ± 169.0 | 4351.3 ± 171.0 |
| Influenza B Yamagata lineage | 350.2 ± 103.6 | 336.2 ± 114.3 |
| Influenza B Victoria lineage | 164.5 ± 178.5 | 234.4 ± 135.0 |
To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in microneutralization antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.
| Proportion of Participants | Benralizumab 30mg | Placebo |
|---|---|---|
| Influenza A H1N1 | 0.420 ± 251.9 | 0.408 ± 191.3 |
| Influenza A H3N2 | 0.440 ± 136.2 | 0.429 ± 168.6 |
| Influenza B Yamagata lineage | 0.280 ± 144.9 | 0.388 ± 115.0 |
| Influenza B Victoria lineage | 0.400 ± 178.7 | 0.388 ± 162.2 |
To compare the change from baseline at Week 12 in mean ACQ-6 score between patients receiving benralizumab 30mg and patients receiving placebo. The ACQ-6 assesses asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short-acting β2 agonist use). Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score is the mean of the responses to each question. Mean scores of ≤0.75 indicate well-controlled asthma, scores between 0.75 and ≤1.5 indicate partly controlled asthma, and a score \>1.5 indicates not well controlled asthma
| Score on a scale | Benralizumab 30mg | Placebo |
|---|---|---|
| Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12 | -0.50 (-2.8 to 4.3) | -0.42 (-2.7 to 1.2) |
Collected over All AEs, including SAEs, were collected from the time the patient, parent, or legal guardian signed the informed consent/assent throughout the treatment period and including the follow-up period (through Week 20).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab 30mg | 0/51 (0%) | 0/51 (0%) | 28/51 (54.9%) |
| Placebo | 0/52 (0%) | 2/52 (3.8%) | 23/52 (44.2%) |
| Event | Benralizumab 30mg | Placebo |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 0/51 | 1/52 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/51 | 1/52 |
| Event | Benralizumab 30mg | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 2/51 | 4/52 |
| HeadacheNervous system disorders | 2/51 | 4/52 |
| Gastroenteritis viralInfections and infestations | 3/51 | 1/52 |
| Upper respiratory tract infectionInfections and infestations | 3/51 | 1/52 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 3/51 | 3/52 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/51 | 2/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/51 | 3/52 |
| Abdominal discomfortGastrointestinal disorders | 2/51 | 0/52 |
| SinusitisInfections and infestations | 2/51 | 1/52 |
| Viral upper respiratory tract infectionInfections and infestations | 2/51 | 0/52 |
| Age, Continuous(Years) | Benralizumab 30mg | Placebo | Total |
|---|---|---|---|
| Mean | 16.0 ± 2.65 | 15.7 ± 2.99 | 15.9 ± 2.82 |
| Age, Customized(Participants) | Benralizumab 30mg | Placebo | Total |
|---|---|---|---|
| ≥12 to ≤17 | 36 | 36 | 72 |
| ≥18 to ≤21 | 15 | 16 | 31 |
| Sex/Gender, Customized(Participants) | Benralizumab 30mg | Placebo | Total |
|---|---|---|---|
| Female | 21 | 21 | 42 |
| Male | 30 | 31 | 61 |
| Race/Ethnicity, Customized(Participants) | Benralizumab 30mg | Placebo | Total |
|---|---|---|---|
| American Indian Or Alaska Native | 0 | 1 | 1 |
| Black Or African American | 13 | 13 | 26 |
| Other | 0 | 2 | 2 |
| White | 38 | 36 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Jan 2017, 6 months.
Results were first posted in Mar 2018, 1 year 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 6 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab